Identification Generic Name (20S)-19,20,22,23-TETRAHYDRO-19-OXO-5H,21H-18,20-ETHANO-12,14-ETHENO-6,10-METHENOBENZ[D]IMIDAZO[4,3-L][1,6,9,13]OXATRIAZACYCLONOADECOSINE-9-CARBONITRILE DrugBank Accession Number DB08676 Background Not Available Type Small Molecule Groups Experimental Structure 
 
 
 Download  MOL SDF PDB SMILES InChI 
 
 
  Similar Structures Structure for (20S)-19,20,22,23-TETRAHYDRO-19-OXO-5H,21H-18,20-ETHANO-12,14-ETHENO-6,10-METHENOBENZ[D]IMIDAZO[4,3-L][1,6,9,13]OXATRIAZACYCLONOADECOSINE-9-CARBONITRILE (DB08676) ×  Close Weight Average: 453.5356  Monoisotopic: 453.216475133  Chemical Formula C 27 H 27 N 5 O 2 Synonyms Not Available Pharmacology Indication Not Available Reduce drug development failure rates Build, train, & validate machine-learning models with evidence-based and structured datasets. See how     Build, train, & validate predictive machine-learning models with structured datasets. See how Contraindications & Blackbox Warnings Avoid life-threatening adverse drug events Improve clinical decision support with information on  contraindications & blackbox warnings, population restrictions, harmful risks, & more. Learn more     Avoid life-threatening adverse drug events & improve clinical decision support. Learn more Pharmacodynamics Not Available Mechanism of action Target Actions Organism U Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha Not Available Humans U Protein farnesyltransferase subunit beta Not Available Humans Absorption Not Available Volume of distribution Not Available Protein binding Not Available Metabolism Not Available Route of elimination Not Available Half-life Not Available Clearance Not Available Adverse Effects Improve decision support & research outcomes With structured adverse effects data, including:  blackbox warnings, adverse reactions, warning & precautions, & incidence rates. Learn more     Improve decision support & research outcomes with our structured adverse effects data. Learn more Toxicity Not Available Pathways Not Available Pharmacogenomic Effects/ADRs  
 
 
 Not Available Interactions Drug Interactions  
 
 
 This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.  Not Available Food Interactions Not Available Categories Drug Categories Not Available Classification Not classified Affected organisms Not Available Chemical Identifiers UNII Not Available CAS number Not Available InChI Key GBEQWWUQNVMGMR-LLHWJCAFSA-N InChI InChI=1S/C27H27N5O2/c28-14-20-5-4-18-12-26(20)34-22-7-6-19-2-1-3-25(23(19)13-22)32-11-9-24(27(32)33)30-10-8-21-15-29-17-31(21)16-18/h1-4,6-7,13,15,17,20,24,26,30H,5,8-12,16H2/t20-,24+,26?/m1/s1 IUPAC Name (5S,18R)-31-oxo-20-oxa-2,6,11,13-tetraazahexacyclo[19.6.2.1^{2,5}.1^{15,19}.0^{9,13}.0^{24,28}]hentriaconta-1(27),9,11,15,21(29),22,24(28),25-octaene-18-carbonitrile SMILES [H][C@]12CCN(C1=O)C1=CC=CC3=C1C=C(OC1([H])CC(CN4C=NC=C4CCN2)=CC[C@]1([H])C#N)C=C3 References General References Not Available External Links PubChem Compound 131704313 PubChem Substance 99445147 ChemSpider 64873355 PDBe Ligand U66 PDB Entries 1ld7 Clinical Trials Clinical Trials  
 
 
 Phase Status Purpose Conditions Count Pharmacoeconomics Manufacturers Not Available Packagers Not Available Dosage Forms Not Available Prices Not Available Patents Not Available Properties State Solid Experimental Properties Not Available Predicted Properties Property Value Source Water Solubility 0.116 mg/mL ALOGPS logP 2.43 ALOGPS logP 1.68 Chemaxon logS -3.6 ALOGPS pKa (Strongest Acidic) 17.66 Chemaxon pKa (Strongest Basic) 7.61 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 83.18 Å 2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 129.92 m 3 ·mol -1 Chemaxon Polarizability 48.58 Å 3 Chemaxon Number of Rings 6 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon Predicted ADMET Features Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9247 Caco-2 permeable + 0.5389 P-glycoprotein substrate Substrate 0.5842 P-glycoprotein inhibitor I Inhibitor 0.5 P-glycoprotein inhibitor II Non-inhibitor 0.7926 Renal organic cation transporter Inhibitor 0.5326 CYP450 2C9 substrate Non-substrate 0.8502 CYP450 2D6 substrate Non-substrate 0.7377 CYP450 3A4 substrate Substrate 0.6391 CYP450 1A2 substrate Inhibitor 0.5888 CYP450 2C9 inhibitor Inhibitor 0.5905 CYP450 2D6 inhibitor Non-inhibitor 0.7424 CYP450 2C19 inhibitor Inhibitor 0.5249 CYP450 3A4 inhibitor Non-inhibitor 0.68 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.7791 Ames test Non AMES toxic 0.5258 Carcinogenicity Non-carcinogens 0.9084 Biodegradation Not ready biodegradable 0.9939 Rat acute toxicity 2.6690 LD50, mol/kg  Not applicable hERG inhibition (predictor I) Weak inhibitor 0.6561 hERG inhibition (predictor II) Non-inhibitor 0.5678    ADMET data is predicted using  admetSAR , a free tool for evaluating chemical ADMET properties. ( 23092397 )  Spectra Mass Spec (NIST) Not Available Spectra Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available Targets Build, predict & validate machine-learning models Use our structured and evidence-based datasets to  unlock newinsights and accelerate drug research. Learn more     Use our structured and evidence-based datasets to unlock new insights and accelerate drug research. Learn more 
 
 
  Details 1.  Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha Kind Protein Organism Humans Pharmacological action Unknown General Function Rab geranylgeranyltransferase activity Specific Function Essential subunit of both the farnesyltransferase and the geranylgeranyltransferase complex. Contributes to the transfer of a farnesyl or geranylgeranyl moiety from farnesyl or geranylgeranyl dipho... Gene Name FNTA Uniprot ID P49354 Uniprot Name Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha Molecular Weight 44408.32 Da References Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [ Article ]  
 
 
  Details 2.  Protein farnesyltransferase subunit beta Kind Protein Organism Humans Pharmacological action Unknown General Function Zinc ion binding Specific Function Essential subunit of the farnesyltransferase complex. Catalyzes the transfer of a farnesyl moiety from farnesyl diphosphate to a cysteine at the fourth position from the C-terminus of several prote... Gene Name FNTB Uniprot ID P49356 Uniprot Name Protein farnesyltransferase subunit beta Molecular Weight 48773.2 Da References Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [ Article ]  × Identify potential medication risks Easily compare up to 40 drugs with our drug interaction checker. Get severity rating, description, and management advice.  Learn more      Drug created at September 15, 2010 21:33 / Updated at June 12, 2020 16:52 